Kornimate/medical-research-clean huggingface dataset:
left versus right radial artery and radiation exposure in patients with predictors of trans-radial failure

Conditions: Coronary Artery Disease

Summary: the aim of this study is to measure radiation exposure during coronary angiography (ca) with a trans-radial approach (tra), specifically comparing access via the left versus right radial artery in patients with suggested clinical predictors of tra failure/difficult. these predictors include age \>70, female gender, height \<64 inches, and history of hypertension.the study also aims to determine difficulties encountered during left or right radial access in this specific patient population. a secondary aim is to compare the results of enrolled patients with a registry of patients where femoral access was obtained. currently more than 1 million percutaneous coronary interventions (pci) are performed in the united states annually. there is a growing trend to perform procedures utilizing the tra due to recent data demonstrating decreased bleeding and access-site complications compared to the femoral approach. however, the tra approach is also know to be associated with greater radiation exposure compared to the femoral approach. furthermore, the tra to catheterization may be difficult in certain populations because of anatomic considerations. though traditionally completed via canalization of the right radial artery (rra) due to feasibility with room setup, left radial artery (lra) access may be superior due to the shorter distance needed to reach the ascending aorta and bypassing the tortuosity of the right subclavian artery. given the benefits of the tra, it is important to determine how left versus right radial artery access affects parameters of radiation exposure in addition to procedural difficulty. this study will be a prospective, randomized study of patients with suggested predictors of tra failure/difficulty referred for coronary angiography. patients referred for coronary angiography using the trans-radial approach will be randomly assigned to obtain arterial access via the right or left radial artery. a registry of patients referred for coronary angiography using the trans-femoral approach will be compiled. the primary outcome measure will be radiation exposure as measured by dose area product output from the coronary angiography system. secondary measures will include the total fluoroscopy time, total dose of radiation, number of catheters used, and incidence of subclavian tortuosity. in addition, procedural complications and success rates will also be evaluated.


Eligibility criteria:
inclusion criteria: patients referred for cardiac catheterization procedure with 3 out of the following 4 characteristics: age ≥70 years, female gender, hypertensive, and ≤64 inches in height. exclusion criteria: patients will be excluded if they 1) underwent prior cabg with utilization of an internal mammary artery, 2) have an abnormal allen test, 3) require emergency cardiac catheterization, 4) are planned to undergo a staged pci procedure, 5) do not consent or are unable to give consent, or 6) are participating in another competing study.
sublingual misoprostol and tranexamic acid in pregnant women with twin pregnancy undergoing cesarean section

Conditions: Cesarean Section Complications

Summary: purpose to evaluate the effects of sublingual misoprostol with or without intravenous tranexamic acid (ta) in comparison with placebo on reducing post-partum hemorrhage in pregnant women with twin pregnancy undergoing an elective cesarean section.

uterine atony is the major cause of postpartum hemorrhage (pph), accounting for up to 80% of pph cases. pph is the leading cause of maternal morbidity and mortality worldwide, resulting in up to 28% of maternal deaths. therefore, inducing a rapid and effective uterine contraction following delivery is an important issue. risk factors of uterine atony include obesity, white or hispanic race/ethnicity, polyhydramnios, preeclampsia, anemia, and chorioamnionitis as well as a twin pregnancy. with the increasingly common use of ovulation induction and assisted reproduction techniques, the incidence of multiple gestation pregnancies has progressively increased. suzuki et al reported that elective cesarean delivery of twin pregnancy at a gestational age of 37 weeks or greater may increase the risk of blood transfusion. several uterotonic agents are used to prevent pph because of uterine atony, including oxytocin, an ergot alkaloid, and prostaglandin. however, there are currently no data to evaluate the efficacy of co-administered sublingual misoprostol and intravenous tranexamic acid on prevention of postpartum hemorrhage in pregnant women with twin pregnancy undergoing an elective cesarean. therefore, this study was designed to evaluate and compare these two new therapeutic options in controlling pph following cs for twin pregnancy

Eligibility criteria:
inclusion criteria: * women with a multiple term pregnancy undergoing elective cesarean section exclusion criteria: * single gestation * placenta praevia and placental abruption * undergoing cesarean section with general anesthesia * women undergoing cesarean section at less than 37 weeks of gestation * with a severe medical disorder * allergy to tranexamic acid or misoprostol

Keywords: cesarean section tranexamic acid postpartum hemorrhage misoprostol
a study of ocrelizumab in comparison with interferon beta-1a (rebif) in participants with relapsing multiple sclerosis

Conditions: Relapsing Multiple Sclerosis

Summary: this randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (rebif) in participants with relapsing multiple sclerosis. participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (iv) as 300 mg infusions on days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a sc three times per week; or interferon beta-1a 44 mcg sc injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks). planned duration of double-blind treatment is 96 weeks. participants who complete the 96-week double-blind treatment will have an option to enter a single-group, active-treatment, open-label extension period, providing they fulfill the eligibility criteria.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis, in accordance with the revised mcdonald criteria (2010) * at least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening) * neurologic stability for greater than or equal to (\>=) 30 days prior to both screening and baseline * expanded disability status scale (edss) score 0 to 5.5 inclusive exclusion criteria: * primary progressive multiple sclerosis * disease duration of more than 10 years in participants with edss less than or equal to (\<=) 2.0 at screening * contraindications for mri * known presence of other neurological disorders which may mimic multiple sclerosis * pregnancy or lactation * requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study * history of or currently active primary or secondary immunodeficiency * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies * active infection, or history of or known presence of recurrent or chronic infection (e.g., hepatitis b or c, human immunodeficiency virus \[hiv\], syphilis, tuberculosis) * history of progressive multifocal leukoencephalopathy * contraindications to or intolerance of oral or iv corticosteroids * contraindications to rebif or incompatibility with rebif use
a study to evaluate elx/tez/iva on cough and physical activity in participants with cystic fibrosis (cf)

Conditions: Cystic Fibrosis

Summary: this study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (elx/tez/iva) on cough and physical activity using wearable technology in cf participants.


Eligibility criteria:
key inclusion criteria: * forced expiratory volume in 1 second (fev1) value ≥30% and ≤90% predicted * heterozygous for cf transmembrane conductance regulator gene (cftr) f508del mutation and a minimal function mutation (f/mf genotypes) key exclusion criteria: * clinically significant liver cirrhosis * solid organ or hematological transplantation * non-ambulatory status * lung infection with organisms associated with a more rapid decline in pulmonary status other protocol defined inclusion/exclusion criteria may apply.
isthmocele after endometrial and non-endometrial suturing in cesarean section

Conditions: Cesarean Section; Dehiscence; Cesarean Wound; Dehiscence

Summary: this study compares the effect of two techniques of uterine closure, with or without endometrial suturing on isthmocele development after cesarean section.

cesarean section is the most common surgery performed on pregnant women. poor healing of the incision of the uterus leads to isthmocele development. long-term morbidities associated with isthmocele are uterine scar pregnancy, uterine perforation, pelvic pain, and spotting-style bleeding after menstruation. many factors that may affect the healing of uterine scar have been studied in the literature (i.e. double or single-layer closure, locked or unlocked closure, uterine retroflection). suturing complete fold of the wound lips during the closure of the uterus may cause the endometrial layer to be embedded in the myometrium and to form niche tissue. the study hypothesized that isthmocele development can be reduced by suturing without enclosing the endometrium during uterine closure.

Eligibility criteria:
inclusion criteria: * term pregnancy (≥37 weeks of gestation) * singleton pregnancy * primary cesarean exclusion criteria: * previous cesarean section * previous uterine surgery * multiple gestations * mullerian anomalies * active labor * placenta previa/accreta
assessment of the anti-inflammatory effects of norflo oro in acute relapses of hla-b27 associated autoimmune uveitis

Conditions: Uveitis

Summary: the purpose of this study is to explore the efficacy of norflo oro in the treatment of relapsing autoimmune uveitis (rau), measured as a long term reduction of the frequency and the severity of relapses, in patients with hla-b27 associated uveitis, under conditions of routine medical practice. the reduction of the mean number of relapses per patient between the year before study treatment and the study period will also be assessed.

the secondary objective of this study will be: (i) evaluation of the improvement of side effects due to hla-b27 associated uveitis such as intraocular pressure (iop), cystoid macular edema, keratophaty and synechia (ii) evaluation of the improvement in uveitis-related symptoms: bcva and symptoms measured by vas, like ocular pain, photophobia, floaters and blurred vision; (iii) evaluation of cell damage and inflammation reduction in patients with hla-b27 associated uveitis; (iv) evaluation of the patients' attitude towards the study treatment and also the evaluation of the safety profile of the study product.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hla-b27 positive related uveitis in non- acute phase * at least one autoimmune uveitis relapse exclusion criteria: * use of supplements (nutraceuticals) or systemic therapy for uveitis with anti-inflammatory immunosuppressive or biological drugs within last 30 days * anticipated need for systemic anti-inflammatory treatment during the study * use of intravitreal peribulbar, sub-tenon, periocular injection in the previous 6 months * long-term treatment with a systemic anti-inflammatory, immune suppressant drugs * woman taking hormonal contraceptives, pregnant or breastfeeding.

Keywords: hla-b27 relapses curcumin
formative research to develop an intervention package to promote practice of kangaroo mother care for low birth weight and preterm infants in a community (ckmc)

Conditions: Low-Birth-Weight

Summary: the study is being conducted to develop an intervention to assess the feasibility of implementing kangaroo mother care (kmc) for low birth weight (lbw) and preterm babies in a community setting. a prototype intervention package will be developed using information obtained from in-depth interviews, focus group discussions and other qualitative research techniques. these interviews will help us identify current behaviours, barriers to adoption of kmc and effective ways to promote kmc in the community. the prototype intervention will be refined by conducting acceptability studies (household trials) with few mothers. the study team are identifying lbw and preterm infants, demonstrating to mothers how to practice kmc and following up till kmc is stopped. the process is being documented using observations and interviews. information is obtained on acceptability of kmc, number of hours per day and number of days kmc was given, breastfeeding practices and support provided by other family members.


Eligibility criteria:
inclusion criteria: * low birth weight or preterm newborns exclusion criteria: * babies with hospitalization criteria * unable to feed or weight less than 1500 grams at birth

Keywords: kmc in community
effect of aging on haemostasis parameters

Conditions: Aging

Summary: aging is an independent risk factor, without any clear explanation. the primary aim of the study is to depict the effect of aging on the coagulation fibrinolysis parameters and microparticles.

patients older than 40, without any acute disease and not receiving any antiaggregant and anticoagulant therapy will be included in the study. blood tests will be performed for coagulation, fibrinolysis and microparticles measurement.

Eligibility criteria:
inclusion criteria: * age \<40 2 groups : 1 : no history of vte 2 : history of vte exclusion criteria: * antiaggregant or anticoagulant therapy at curative dose * arterial or thrombotic event in the last month

Keywords: venous thromboembolism risk, elderly, hypercoagulability fibrinolysis microparticles
effects of vitamin b12 treatment in singers

Conditions: Vitamin B 12 Deficiency

Summary: in this study, the investigators aim to assess if vitamin b12 treatment demonstrates a beneficial effect on voice performance. if so, they wish to examine the relationship between the vitamin b12 treatment and the study participant's general well-being.

through the investigators' experience, they have observed that amongst singers and voice professionals, there is a common belief that there are voice benefits from cobalamin treatment. consequently, some singers and voice professionals tend to ask for cobalamin injections in order to enhance their vocal performance. however, there are no previous reports that illustrate the effects of vitamin b12 deficiency or treatment on voice performance.

Eligibility criteria:
inclusion criteria: * aged 18 to 65 years old * an active singer who is presently singing * willing and able to comply with the study requirements * completed and signed an informed consent form. exclusion criteria: * known vitamin b12 deficiency * active or recent vitamin b12 treatment (the subject must not receive vitamin b12 treatment for at least 4 weeks) * any known bleeding disorder * any known laryngeal pathology * plans to start any new treatment, oral/parenteral anticoagulant, supplement, or medication during the study period * scored above the highest 10 percentile of performance in all three voice evaluation questionnaires will be withdrawn from the study before the first injection (i.e., scored less than or equal to 7 in the voice fatigue index (vfi), less than or equal to 6 in the evaluation of the ability to sing easily (ease), and less than or equal to 4 in the singing voice handicap index 10 (svhi-10))
factors associated with late hiv diagnosis in grampian: an epidemiological study

Conditions: Human Immunodeficiency Virus

Summary: human immunodeficiency virus (hiv) is a major global health concern which has resulted in an estimated 39 million deaths world-wide. although it is now a treatable medical condition there is still avoidable morbidity and mortality associated with hiv infection in the uk. late diagnosis (cd4 count of \<350 cells/mm3 or aids-defining illness irrespective of cd4 count) is associated with increased morbidity and mortality, increased risk of transmission, impaired response to antiretroviral therapy and increased healthcare costs. in grampian, 49% of patients were diagnosed late between 1984 and 2011. therefore, the aim of the study is to determine the factors associated with late hiv diagnosis in grampian between 2009 and 2014 to ascertain whether diagnoses could have been made earlier. the study constitutes a secondary data analysis. individuals newly diagnosed with hiv between january 2009 and december 2014 were identified from a health protection scotland (hps) database. the majority of outcome data were extracted from the existing hps database. missing data were collected via a retrospective review of patient case-notes, laboratory reports and an electronic patient management system. patients were classified as early or late diagnosis and comparisons were made between the groups using statistical tests. the study sought to provide a basis for recommendations for improvement of information and services to facilitate earlier hiv diagnosis in grampian.


Eligibility criteria:
inclusion criteria: * individuals diagnosed with hiv between january 2009 and december 2014 * individuals diagnosed in nhs grampian exclusion criteria: * individuals aged \< 16 years of age

Keywords: hiv human immunodeficiency virus late diagnosis
first step with singulair® therapy (0476-323)

Conditions: Asthma

Summary: in adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose inhaled corticosteroids (ics) in improving asthma symptom control or satisfaction over a 6 week comparison period.


Eligibility criteria:
inclusion criteria: * first time diagnosis of mild asthma symptoms which requires an antiinflammatory controller medication * patients not controlled with short acting beta2 agonist (sab) therapy (requiring more than one treatment per week but less than 7 per week) * patients dissatisfied with low dose ics therapy, or patients reluctant to take ics therapy, or patients insufficiently controlled due to non-compliance with low dose ics therapy through out the preceding 6 weeks * patient's forced expiratory volume in one second (fev1) is \< 80% of predicted value exclusion criteria: * patient on combination therapy * patient on long acting beta2 agonists * patient on using moderate to high doses of ics. (ics \>250 \&micro g/day flovent\&reg; or equivalent per day)
the use of an acellular dermal matrix in a two-staged breast reconstruction

Conditions: Mastectomy; Postoperative Pain; Complications

Summary: this study intends to compare postoperative outcomes of a tissue expander placement following a mastectomy with two different operative techniques. this study will be randomized and double blinded comparing the traditional placement of the tissue expander under an inferolateral serratus muscle flap to a new technique which uses an acellular dermal matrix as an inferolateral sling, instead of the muscle flap. the study we are proposing will evaluate the question of whether there is a difference between the traditional method of serratus flap and the new technique of using an acellular matrix with tissue expander placement. this will be a double blinded randomized study of thirty women in each group comparing outcomes which will include postoperative pain, complications (wound infection, hematoma, capsular contracture, etc), and patient satisfaction with the procedure.


Eligibility criteria:
inclusion criteria: * patients presenting to dr. wendel's clinic who are older than 17 years of age undergoing a mastectomy and wish to have breast reconstruction with a tissue expander or those who have previously undergone a mastectomy and are now seeking reconstruction will be solicited for the study. exclusion criteria: * preoperative radiation therapy * autoimmune disease * fever * uncontrolled diabetes mellitus * inability to comprehend or cooperate with postoperative instructions * local or systemic infection * have any allergies to the excipient ingredients found in the matrix * pregnancy * low vascularity of the surrounding tissue * mechanical trauma * poor nutrition * poor general medical condition

Keywords: acellular dermal matrix breast reconstruction tissue expander postoperative pain complication pain patient satisfaction
effectiveness of stellate ganglion block in individuals with parkinson's disease

Conditions: Parkinson Disease

Summary: the goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in patients with parkinson's disease. the main question it aims to answer are: • can stellate ganglion block improve the dysphagia and activities of daily living in patients with parkinson's disease. participants will be divided into the the control group and observation group evenly. all the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. the swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

dysphagia, or swallowing difficulty, is a common symptom associated with parkinson's disease. it is characterized by weakened chewing and throat muscles, leading to difficulties in eating, coughing, and a sensation of choking in individuals with parkinson's disease. the goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in patients with parkinson's disease. the main question it aims to answer are: • can stellate ganglion block improve the dysphagia and activities of daily living in patients with parkinson's disease. participants will be divided into the the control group and observation group evenly. all the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. the swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

Eligibility criteria:
inclusion criteria: * age \>18 years. * meeting the diagnostic criteria for parkinson's disease developed by the neurology branch of the - - chinese medical association in 2006. * diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study. * stable vital signs, conscious, able to cooperate with assessment and treatment. exclusion criteria: * dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases. * history of mental diseases or use of antipsychotics. * complicated with cognitive impairment or consciousness dysfunction. * simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases.